All News

Today is June 04, 2023. All times in Eastern Daylight Time.

Research Results from Ontada HOPE Studies Presented at ASCO 2023 Illuminate How Social Determinants of Health Impact Different Patient Populations with Triple-Negative Breast Cancer

06/04/2023 - 09:00 AM

BUSINESS WIRE
Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting

06/04/2023 - 09:00 AM

BUSINESS WIRE
Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

06/04/2023 - 08:00 AM

BUSINESS WIRE
Nucleai and Mayo Clinic BioPharma Diagnostics Announce Strategic Collaboration to Transform Digital Pathology for Drug Development and Clinical Practice

06/04/2023 - 08:00 AM

BUSINESS WIRE
TAGRISSO® achieved unprecedented survival in early-stage EGFR-mutated lung cancer, with 88% of patients alive at five years in ADAURA Phase III trial

06/04/2023 - 08:00 AM

BUSINESS WIRE
ELAHERE® Demonstrates 35% Reduction in the Risk of Disease Progression or Death Versus Chemotherapy in FRα-Positive Platinum-Resistant Ovarian Cancer

06/04/2023 - 08:00 AM

BUSINESS WIRE
Promising Data for Investigational Innovative Bispecific Ivonescimab Featured at ASCO 2023

06/04/2023 - 08:00 AM

BUSINESS WIRE
Drive Shack Inc. Modifies Tax Benefits Plan

06/04/2023 - 05:00 AM

BUSINESS WIRE
La Fundación del Movimiento por la Seguridad del Paciente concluye la 10.a Cumbre mundial sobre ciencia, tecnología y seguridad del paciente

06/03/2023 - 08:55 PM

BUSINESS WIRE
Mountain Valley Pipeline To Proceed

06/03/2023 - 02:41 PM

BUSINESS WIRE
New PATHFINDER Study Analysis Demonstrates Efficient Diagnostic Resolution Following Multi-Cancer Early Detection Testing

06/03/2023 - 02:15 PM

BUSINESS WIRE
GRAIL Presents Real-World Experience With The Galleri® Multi-Cancer Early Detection Test At 2023 ASCO Annual Meeting

06/03/2023 - 02:15 PM

BUSINESS WIRE
Riassunto: La Patient Safety Movement Foundation conclude il suo 10o summit mondiale annuale per la sicurezza dei pazienti, la scienza e la tecnologia

06/03/2023 - 01:41 PM

BUSINESS WIRE
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study

06/03/2023 - 01:30 PM

BUSINESS WIRE
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study

06/03/2023 - 01:30 PM

BUSINESS WIRE
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of SentinelOne, Inc. (S) on Behalf of Investors

06/03/2023 - 12:00 PM

BUSINESS WIRE
Exai Bio Presents New Multi-Cancer Early Detection Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

06/03/2023 - 09:05 AM

BUSINESS WIRE
Preliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Clinical Activity and Generally Well Tolerated Safety Profile

06/03/2023 - 09:00 AM

BUSINESS WIRE
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Reduced the Risk of Event-Free Survival Events by 42% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB NSCLC

06/03/2023 - 09:00 AM

BUSINESS WIRE
A Patient Safety Movement Foundation conclui seu 10o Encontro Anual da Cúpula Mundial de Segurança do Paciente, Ciência e Tecnologia

06/03/2023 - 08:37 AM

BUSINESS WIRE
Die Patient Safety Movement Foundation schließt ihren 10. jährlichen Weltgipfel für Patientensicherheit, Wissenschaft und Technologie ab

06/03/2023 - 08:37 AM

BUSINESS WIRE
Massive Bio and The Oncology Institute (TOI) Forge Partnership to Revolutionize Cancer Care and AI-enabled Cancer Research

06/03/2023 - 08:00 AM

BUSINESS WIRE
LYNPARZA® (olaparib) and IMFINZI® (durvalumab) combination reduced risk of disease progression or death by 37% vs. chemotherapy and bevacizumab in patients with advanced ovarian cancer without tumor BRCA mutations in the DUO-O Phase III trial

06/03/2023 - 08:00 AM

BUSINESS WIRE
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Unresectable Advanced Pleural Mesothelioma

06/03/2023 - 08:00 AM

BUSINESS WIRE
La Patient Safety Movement Foundation conclut son 10e Sommet mondial annuel sur la sécurité des patients, la science et la technologie

06/03/2023 - 07:31 AM

BUSINESS WIRE

1 2 3 4 5 6 7 8 9 10 11 ... 585

Next »

Search